StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

Analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Saturday. The firm set a “hold” rating on the medical research company’s stock.

Several other research firms also recently weighed in on CTSO. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Monday, January 13th. HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Cytosorbents stock opened at $1.15 on Friday. The stock has a market capitalization of $62.88 million, a P/E ratio of -3.19 and a beta of 0.61. The company’s fifty day moving average price is $1.01 and its 200 day moving average price is $1.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.61.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Millennium Management LLC acquired a new stake in shares of Cytosorbents in the fourth quarter valued at approximately $30,000. Renaissance Technologies LLC grew its holdings in Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares in the last quarter. Northern Trust Corp increased its stake in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after acquiring an additional 16,701 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Cytosorbents during the 4th quarter worth $99,000. Finally, Geode Capital Management LLC boosted its position in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares during the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.